MedInvest to Host Biotech and Pharma Investor Conference on March 31 & April 1, 2026 in New York City
MedInvest, a leading healthcare, biotech, and medtech media and conference company, will host its semi-annual Biotech and Pharma Investor Conference in New York City on March 31 and April 1, 2026. The National Institutes of Health, National Cancer Institute, Webster Bank and Pillsbury will be presenting partners of the event.
The conference is expected to attract 100+ investors spanning venture and public funds, family offices, strategics, and government and non-profit grant making entities. The two-day event will consist of half a dozen talks by KOLs and investor panels.
During, before and after the conference for two weeks, meetings will be facilitated both in person and virtually via the conference’s partnering system.
Speakers include:
Dr. Ronan O'Hagan, CEO, Bectas Therapeutics | Former Executive Director, Oncology Drug Discovery for Merck | Former CSO, Xilio Therapeutics
Dr. Phil Friedlander, Professor, Medicine, Hematology and Medical Oncology, Mt. Sinai | Lead PI Iovance Trial
Dr. Alfred Slanetz, Former CEO, Bluebird Bio | Chairman, National Foundation for Cancer Research
Dr. Darryl Davis, Professor, University of Ottawa
Steven Ferguson, Special Advisor, National Institutes of Health
Dr. Michael Salgaller, Supervisory Specialist, NIIH/NCI Technology Transfer Center
Allan Gobbs, Founder and Managing Partner, ATEM Capital
Brooke Raphael, COO, Avicella Capital
Dr. Max Colbert, Associate, Medical Excellence Capital
Karen Harris, Executive Director, Mission Related Investments and Finance, Alzheimer's Drug Discovery Foundation
Steven Abernathy, Founder and CEO, Abernathy Family Office
Sherry Grisewood, Senior Investment Officer, FoxHill Asset Management (FO)
Dan Farrell, Founder and CEO, Privos Capital
Steven Green, Partner, Pillsbury
Lillian Kim, Partner, Pillsbury